ArticleHuman vaccines & immunotherapeutics2022
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study
A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Risk of cervical cancer and high-grade lesions in vulnerable women a systematic review and meta-analysis.Nature communications · 2026Pooled it
- Updated clinical practice guidelines for human papillomavirus vaccination: the Korean Society of Gynecologic Oncology recommendations.Journal of gynecologic oncology · 2026Guideline
- Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.The Cochrane database of systematic reviews · 2025Pooled it
- Comparative effectiveness and immunogenicity of single-dose and multi-dose human papillomavirus vaccination: a systematic review.BMC public health · 2025Pooled it
- Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials.Human vaccines & immunotherapeutics · 2023Trial
- Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.Human vaccines & immunotherapeutics · 2026Article
- Natural Versus Vaccine-Induced Immunity Against HPV: A Comparative Review of Antibody Response and Cancer Prevention.Antibodies (Basel, Switzerland) · 2026Review
- Age of acquisition of disease-causal human papillomavirus infection to high-grade cervical intraepithelial neoplasia (CIN2+) in England.BMC infectious diseases · 2026Article
- The human papilloma virus (HPV) vaccination recommendations and funded programs for adults: A targeted literature review.Human vaccines & immunotherapeutics · 2025Review
- Revisiting HPV vaccination post-COVID: geopolitical, sociocultural, and ethical disparities in global health.International journal for equity in health · 2025Review
- HPV Testing, Self-Collection, and Vaccination: A Comprehensive Approach to Cervical Cancer Prevention.Current oncology (Toronto, Ont.) · 2025Review
- Development and Validation of the Knowledge of Human Papillomavirus Scale in Japan.Healthcare (Basel, Switzerland) · 2025Article
- Article
- A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers.Virology journal · 2025Review
- Opportunities and challenges for human papillomavirus vaccination in China.Human vaccines & immunotherapeutics · 2024Review
- The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age.Human vaccines & immunotherapeutics · 2024Article
- Estimation of self-funded human papillomavirus vaccine recipients from Japan's previously assumed "unvaccinated generation".Cancer science · 2024Article
- Cancer-preventing vaccination programs in prison: promoting health equity in Europe.The Lancet regional health. Europe · 2024Review
- The Immune Response Generated against HPV Infection in Men and Its Implications in the Diagnosis of Cancer.Microorganisms · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was also generally well tolerated and highly immunogenic in men aged 27-45 years who participated in the single-cohort mid-adult male (MAM) study (NCT01432574; n = 150). Here, we report results of a long-term follow up (LTFU) extension of FUTURE III with up to 10 years follow-up. To understand the relevance of the mid-adult women LTFU study in the context of mid-adult men vaccination, we report results from post-hoc, cross-study immunogenicity analyses conducted to compare immunogenicity (geometric mean titers; GMTs) at 1-month post-qHPV vaccine dose 3 in women and men aged 27-45 years versus women and men aged 16-26 years from prior efficacy studies. The qHPV vaccine demonstrated durable protection against the combined endpoint of HPV6/11/16/18-related high-grade cervical dysplasia and genital warts up to 10 years (median 8.9) post-dose 3 and sustained HPV6/11/16/18 antibody responses through approximately 10 years in women aged 27-45 years. Efficacy of qHPV vaccine in men aged 27-45 years was inferred based on the cross-study analysis of qHPV vaccine immunogenicity demonstrating non-inferior HPV6/11/16/18 antibody responses in men aged 27-45 years versus 16-26 years. In conclusion, durable effectiveness of the qHPV vaccine was demonstrated in women 27-45 years of age, and vaccine efficacy was inferred in men 27-45 years of age based on the serological results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.